Therapeutic Application of Corticosteroids in COVID-19 : A Focus on Optimum Dose and Duration of Therapy
| Errataetall: |
CommentOn: BMC Infect Dis. 2021 Apr 10;21(1):337. - PMID 33838657 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - 61(2021), 9 vom: 21. Sept., Seite 1145-1148 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khiali, Sajad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 16.08.2021 Date Revised 10.09.2021 published: Print-Electronic CommentOn: BMC Infect Dis. 2021 Apr 10;21(1):337. - PMID 33838657 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcph.1929 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327044861 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327044861 | ||
| 003 | DE-627 | ||
| 005 | 20231225195915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.1929 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327044861 | ||
| 035 | |a (NLM)34157144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khiali, Sajad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Application of Corticosteroids in COVID-19 |b A Focus on Optimum Dose and Duration of Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2021 | ||
| 500 | |a Date Revised 10.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: BMC Infect Dis. 2021 Apr 10;21(1):337. - PMID 33838657 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a acute respiratory distress syndrome (ARDS) | |
| 650 | 4 | |a corticosteroid | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a methylprednisolone | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 61(2021), 9 vom: 21. Sept., Seite 1145-1148 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2021 |g number:9 |g day:21 |g month:09 |g pages:1145-1148 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.1929 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 9 |b 21 |c 09 |h 1145-1148 | ||